Product news from the 05/23/06 News Brief

Share this article:
The FDA approved the first generic version Forest Laboratories’ Lexapro (escitalopram oxalate) to treat major depression, according to a posting on the agency’s Web site. The decision means that Ivax Corporation of Miami, a division of Israel’s Teva Pharmaceuticals, is the first company cleared to market a generic Lexapro version in 5, 10 and 20 milligram doses.Behind Pfizer’s Zoloft, Lexapro was the number No. 2 selling antidepressant in US in 2005, according to IMS Health figures, with US sales reaching approximately $2.1 billion last year. The FDA has approved Centocor’s Remicade (infliximab) for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy. This approval establishes Remicade as the first and only biologic therapy approved for the treatment of pediatric Crohn's disease. Remicade was first approved in the US as a treatment for adult CD in 1998.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.